GPhA OUTLINES AGENDA FOR NEW FDA COMMISSIONER

JULY 01, 2006

Officials at the Generic Pharmaceutical Association (GPhA) are wasting no time in letting incoming FDA Commissioner Andrew von Eschenbach, MD, know what they will be expecting from him. In a statement welcoming Dr. von Eschenbach to the FDA, GPhA President and Chief Executive Officer Kathleen Jaeger said that the appointment of "a permanent commissioner is an absolute necessity at a federal agency that has such a direct impact on the health and well-being of America's citizens."

Jaeger urged the new FDA chief to move quickly "to appropriately address important issues, such as an abbreviated approval pathway for generic biopharmaceuticals, authorized generics, the timely approval of generic medicines, and increased funding for the Office of Generic Drugs."




SHARE THIS SHARE THIS
0
 

In Seniors: Consider CMV Serostatus
When Recommending Flu Vaccine

Older people who have cytomegalovirus seem to have less robust responses to the trivalent influenza vaccine than those who do not have CMV.


 

 

Conference Coverage
News from the year's biggest meetings


Pharmacist Education
Clinical features with downloadable PDFs


 

SIGN UP FOR THE PHARMACY TIMES NEWSLETTER
Personalize the information you receive by selecting targeted content and special offers.